Ticker brief

OABI

last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
28
authors 14d
20
crowd 14d
+0.54

No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.

Sentiment — last 14 days
daily mean sentiment, 2026-08-17 → 2026-08-21 · now +0.45 (−1 bearish … +1 bullish)
Who spoke20
authorgradetrader scoresignalsmean sent
@BAlmohsin1C-0.913+0.37
@Brad_E_SchulzC·3+0.00
@wallstengineB-1.902+0.53
@EmmanuelInvestC-1.112+0.62
@BriefingcomB+0.502+0.45
@OptionsFlowBossC·2+0.35
@MrGannabcC-0.451+0.50
@DekmarTradesC-1.241+0.40
@dmdt14C-1.881+0.65
@theflynewsC·1+0.45
@doublejtradingC-1.821+0.00
@BankTheTradeC+1.631+0.65
@OpenOutcrierC·1+0.60
@optionscjpC-1.281+0.50
@Volume_StocksC-3.241+0.50
@MartinShkreliB+1.421+0.80
@AlertsAndNewsC-1.901+0.50
@AponiaAnalyticsB+4.911+0.60
@equityddC-2.031+0.75
@OptimalinvestmeC+1.551+0.45
Recent signals28of 28 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-08-21@Optimalinvestme+0.45Lists stocks bought and held before the close; output is capped at the first six tickers.·
2026-08-20@equitydd+0.75Bullish OABI thesis cites partners, pipeline growth, royalties and raised 2026 guidance.·
2026-08-18@OptionsFlowBoss+0.00Presents OABI open-interest changes without a stated direction.·
2026-08-18@BAlmohsin1+0.60The author recaps hypothetical gains from four completed educational setups during Monday's session.·
2026-08-17@Brad_E_Schulz+0.00Lists stocks gaining at least 4% on elevated volume; capped at the first six names.·
2026-08-17@AponiaAnalytics+0.60Argues Lilly's $370M collaboration validates a broader OABI discovery platform.·
2026-08-17@BAlmohsin1+0.50Arabic recap reports simulated gains across four completed educational trades.·
2026-08-17@OptionsFlowBoss+0.70Quantifies unusual bullish options volume across several stocks.·
2026-08-17@Brad_E_Schulz+0.00Reports intraday sector returns, breadth and leaders; capped at the first six directly quantified tickers.·
2026-08-17@Brad_E_Schulz+0.00Lists stocks up at least 4% on elevated average volume; capped at the first six names.·
2026-08-17@AlertsAndNews+0.50OmniAb announced a licensing collaboration with Eli Lilly worth up to $370M.·
2026-08-17@MartinShkreli+0.80Bullish OABI thesis cites a newly announced Lilly deal and a $15 author target.·
2026-08-17@BAlmohsin1+0.00Premarket watchlist explicitly says inclusion does not mean entry.·
2026-08-17@Volume_Stocks+0.50Premarket roundup reports distinct partnerships, insider buying, supply momentum and deployment milestones.·
2026-08-17@optionscjp+0.50Premarket list reports direct catalysts including deals, buyback, earnings, initiation and a Phase 3 miss.·
2026-08-17@Briefingcom+0.50OmniAb signed a Lilly collaboration and license deal and raised 2026 cash guidance.·
2026-08-17@OpenOutcrier+0.60OmniAb announced a global collaboration and licensing agreement with Eli Lilly.·
2026-08-17@Briefingcom+0.40Lists the largest premarket gaps, capped at the first six tickers by stated move magnitude.·
2026-08-17@BankTheTrade+0.65Reports a global licensing collaboration under which OmniAb may receive up to $370M plus royalties from Lilly.·
2026-08-17@doublejtrading+0.00Publishes a broad gapper list without individual directional interpretation.·
2026-08-17@theflynews+0.45Reports OmniAb's collaboration and license agreement with Eli Lilly.·
2026-08-17@dmdt14+0.65Reports OABI broke 3.90, identifies 3.80 support, and watches 4.60·
2026-08-17@EmmanuelInvest+0.50OmniAb raises year-end cash guidance and announces a milestone-rich Lilly collaboration.·
2026-08-17@DekmarTrades+0.40OmniAb announced a collaboration and licensing agreement with Eli Lilly.·
2026-08-17@EmmanuelInvest+0.75OmniAb and Lilly announce a global licensing collaboration worth up to $370M plus royalties.·
2026-08-17@MrGannabc+0.50Lists breakout, upside objectives and stop levels without explicit entry intent.·
2026-08-17@wallstengine+0.50OmniAb raised its 2026 year-end cash guidance to $49M-$53M from $37M-$41M.·
2026-08-17@wallstengine+0.55OmniAb signed a global drug-discovery collaboration with Lilly worth up to $370M plus royalties.·

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.